Resverlogix commences dosing of patients in Phase 2b COVID-19 study

Resverlogix commences dosing of patients in Phase 2b COVID-19 study

Patients have received their first dose of apabetalone

Format

JPEG

Source

Resverlogix Corp

Téléchargements